EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ivermectin inhibits ER, HER2, and TGF-β pathways in ER-positive and endocrine-resistant breast cancer cells

Kitiya Rujimongkon iD, Patthamapon Adchariyasakulchai, Chanoknun Boonyaratsewee, Kantasorn Horpratraporn, Wannarasmi Ketchart iD

PLOS One · 30.04.2026 · 21 (4) · e0348260

DOI: 10.1371/journal.pone.0348260 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 30.04.2026. Verfasst von Kitiya Rujimongkon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Ivermectin, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Transforming Growth Factor beta. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thailand Science research and Innovation Fund Chulalongkorn University, Ratchadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ivermectin (IVM), initially developed as an antiparasitic drug, has recently demonstrated notable anticancer activity in several malignancies, including breast cancer. Our previous work showed that IVM inhibited cell proliferation and invasion in breast cancer cells, primarily through modulation of the Wnt signaling pathway. Preliminary results further indicated that combining IVM with tamoxifen enhanced its antiproliferative effects in endocrine-resistant breast cancer cells, suggesting a potential role in overcoming drug resistance. To further clarify IVM’s mechanism in the context of endocrine resistance, this study investigated its effects on estrogen receptor-positive (ER⁺) and endocrine-resistant breast cancer cells. IVM significantly suppressed estrogen-induced proliferation and downregulated key resistance-associated markers, including ER and HER2. Additionally, IVM treatment markedly reduced ERK, a downstream effector linked to HER2 and TGF-β signaling. This inhibition was accompanied by a decrease in phosphorylated SMAD2 (pSMAD2) within the TGF-β pathway, while levels of SMAD4—a factor associated with favorable prognosis in endocrine resistance—were maintained. Collectively, these findings highlight IVM’s potential as a repurposed therapeutic agent, with the dual capacity to prevent endocrine resistance in ER⁺ breast cancer and to enhance anti-hormonal therapies in resistant cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IvermectinBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesTransforming Growth Factor betaSignal TransductionDrug Resistance, NeoplasmReceptors, EstrogenHumansFemaleCell ProliferationCell Line, TumorSmad2 ProteinPhosphorylationSmad4 Protein

Substanzen

IvermectinErb-b2 Receptor Tyrosine KinasesTransforming Growth Factor betaReceptors, EstrogenSmad2 ProteinERBB2 protein, humanSmad4 Protein

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.

ORCID-Profile: Kitiya Rujimongkon, Wannarasmi Ketchart

Förderung

  • Thailand Science research and Innovation Fund Chulalongkorn University
  • Ratchadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn University

Zitieren

APA

Rujimongkon, K., Adchariyasakulchai, P., Boonyaratsewee, C., Horpratraporn, K., & Ketchart, W. (2026). Ivermectin inhibits ER, HER2, and TGF-β pathways in ER-positive and endocrine-resistant breast cancer cells. PLOS One, 21(4), e0348260. https://doi.org/10.1371/journal.pone.0348260

Vancouver

Rujimongkon K, Adchariyasakulchai P, Boonyaratsewee C, Horpratraporn K, Ketchart W. Ivermectin inhibits ER, HER2, and TGF-β pathways in ER-positive and endocrine-resistant breast cancer cells. PLOS One. 2026;21(4):e0348260. doi:10.1371/journal.pone.0348260

BibTeX
@article{Rujimongkon2026,
  author = {Rujimongkon, Kitiya and Adchariyasakulchai, Patthamapon and Boonyaratsewee, Chanoknun and Horpratraporn, Kantasorn and Ketchart, Wannarasmi},
  title = {Ivermectin inhibits ER, HER2, and TGF-β pathways in ER-positive and endocrine-resistant breast cancer cells},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {4},
  pages = {e0348260},
  doi = {10.1371/journal.pone.0348260}
}
Kostenlos starten →